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Abstract
Activation of inflammatory cells is central to the pathogenesis of autoimmune demyelinating diseases of the peripheral
nervous system. The novel chimeric compound quinpramine—generated from imipramine and quinacrine—redistributes
cholesterol rich membrane domains to intracellular compartments. We studied the immunological and clinical effects of
quinpramine in myelin homogenate induced Lewis rat experimental autoimmune neuritis (EAN), a model system for acute
human inflammatory neuropathies, such as the Guillain-Barre ´ syndrome. EAN animals develop paresis of all limbs due to
autoimmune inflammation of peripheral nerves. Quinpramine treatment ameliorated clinical disease severity of EAN and
infiltration of macrophages into peripheral nerves. It reduced expression of MHC class II molecules on antigen presenting
cells and antigen specific T cell proliferation both in vitro and in vivo. Quinpramine exerted its anti-proliferatory effect on
antigen presenting cells, but not on responder T cells. Our data suggest that quinpramine represents a candidate
pharmaceutical for inflammatory neuropathies.
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Introduction
Acute inflammatory neuropathies are rare [1], but often
severely disabling disorders of the peripheral nervous system and
are associated with relevant morbidity and mortality [2]. Current
therapeutic options remain incompletely effective [3].
The prototypic acute inflammatory neuropathy Guillain–
Barre ´ syndrome (GBS) most commonly manifests as ascending
flaccid tetraparesis with less pronounced sensory deficits [4]. Its
clinical course and long-term outcome are highly variable [2]
and the prognosis is thought to be determined by the degree of
axonal loss. Demyelinating and axonal variants can be
distinguished [5]. In the demyelinating variants histopathology
features multifocal mononuclear cell infiltration, demyelination
and secondary axonal loss [6]. These pathological characteris-
tics are recapitulated in experimental autoimmune neuritis
(EAN), an animal model of GBS that can be induced in
susceptible rodent strains by active immunization or passive
t r a n s f e rp a r a d i g m s[ 7 ] .T h i sa n i m a lm o d e lh a se n a b l e dt e s t i n g
of multiple experimental therapies aimed at ameliorating GBS
in a preclinical setting [8].
A promising novel compound for the possible future treatment
of inflammatory disorders of the nervous system has recently been
identified. In an in vitro screen for compounds inhibiting prion
protein amplification the chimeric drug quinpramine – fused from
the anti-depressant imipramine and the malaria treatment
quinacrine – was highly effective [9]. Mechanistic studies
suggested that the anti-prion effect is co-mediated by redistributing
cholesterol to intracellular compartments [9]. The organization of
antigen presenting molecules at the immunological synapse is
associated with cholesterol distribution in cellular membrane
microdomains [10,11]. It was thus conceivable - though previously
unknown - that quinpramine could also be effective in inflamma-
tory diseases [12].
In experimental autoimmune encephalomyelitis (EAE) – the
animal model of multiple sclerosis – quinpramine reduced clinical
disease severity in both a preventive and therapeutic paradigm
[13]. Quinpramine treatment also improved histopathological
indicators of EAE severity. Splenocytes from quinpramine treated
animals exhibited reduced antigen-specific T cell proliferation and
secretion of the pro-inflammatory cytokines IFN-c and IL-17 [13]
indicating a reduced autoimmune activation due to quinpramine
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Therefore, we assessed the clinical and immunological efficacy of
quinpramine in EAN and studied the underlying mechanism of
effect.
Materials and Methods
Induction of experimental autoimmune neuritis
EAN was induced as previously described [14]. Briefly, female
Lewis rats (150–200 grams) aged 8–12 weeks (Charles River
Laboratories) received subcutaneous injections (200 ml) in the hind
footpad of 6–8 mg of bovine peripheral nerve myelin (BPNM)
generated as previously described [15] emulsified in 100 ml PBS
and mixed with 100 ml complete Freund’s adjuvant (CFA, Difco)
containing 1 mg/ml heat inactivated Mycobacterium tuberculosis
(H37Ra). Severe and moderate EAN were induced with 8 and
6 mg of BPNM per animal, respectively. Four independent EAN
treatment experiments were performed. All experiments contained
at least three experimental groups: no EAN, EAN vehicle and
EAN quinpramine therapeutic. In sum, 30 animals were analyzed
per treatment group (4–10 animals per group per experiment).
Two of the four total experiments additionally contained
experimental groups for quinacrine and preventive quinpramine
treatment (4–10 animals per group per experiment), respectively.
Clinical scoring was performed work-daily by an observer blinded
towards treatment (A.K.M.) and the score ranged from grade 0 to
10 (0—no signs to 10—death) as previously described [16].
Animal experimentation was approved by local state authorities
(Landesamt fu ¨r Natur, Umwelt und Verbraucherschutz Nordr-
hein-Westfalen) under the approval reference number 8.87-
50.10.34.08.336.
Quinpramine treatment
Quinpramine was synthesized as previously described [9,17].
Animals were randomized to receive oral treatment with
quinpramine solution by oral gavage by force feeding three times
per week starting at day 2 after immunization (preventive) or
starting at day 10 after immunization (therapeutic). Quinpramine
was dissolved in 5% of total volume 100% ethanol and then
diluted with 95% safflower oil. The drug-oil emulsion was
prepared freshly every day and was adjusted to the animals’ body
weight respectively. Treatment (2 mg/200 ml solution/rat) was
performed three times per week corresponding to a final dose of
6 mg/week/rat. Control animals were fed 5% ethanol/95%
safflower oil mixture only. In an initial experiment, Quinpramine
dosages between 6–15 mg/week/rat were tested, but did not
further improve treatment responses, while eliciting no observable
adverse effects (data not shown). Three subsequent independent
quinpramine treatment experiments (n=6–10 per treatment
group) were performed using the 6 mg/week/rat dosage. In a
control experiment, EAN rats (n=6) received the quinpramine
precursor substance quinacrine (2 mg/200 ml solution/rat) diluted
in 5% ethanol/95% safflower oil mixture by force feeding three
times per week. For in vitro application, quinpramine was dissolved
in DMSO (1 mg/ml) and used at a final concentration of 50–
200 nM for 1–24 hours in quadruplicate wells.
Histology
At the peak of EAN severity (day 14 post immunization) a
randomly chosen half of the treated group (n=5) was sacrificed by
CO2 narcosis and sciatic nerves were dissected and paraffin or
epoxy resin embedded as previously described [18]. Paraffin
sections (10 mm) were stained with haematoxylin/eosin and an
anti-CD68 (ED1, Serotec) or anti-MHC-II antibody (MCA2687R,
Serotec) using DAB based staining as previously described [19].
The entire nerve cross section was photographed using a
conventional microscope (Axioplan 2, Carl Zeiss) and the digital
photographs were photomerged using Adobe Photoshop CS3
software (Adobe Systems). The nerve cross sectional area occupied
by mononuclear cell infiltrates was measured and the number of
CD68 positive and MHC-II positive nuclei was counted using
ImageJ software (v1.41, NIH). Semi thin (0.5 mm) section were cut
from epoxy resin embedded sciatic nerves, stained with methylene-
blue as previously described [18] and photographed.
Filipin staining
The murine macrophage cell line RAW264.7 (ATCC) was
cultured in the presence of quinpramine (200 nM) for six days
before staining for cholesterol with filipin (25 mg/ml, Sigma) in
90% glycerol and 1.5 mg/ml glycin in PBS for 30 minutes at
room temperature. Stained cells were photographed using a
conventional microscope (Axioplan 2, Carl Zeiss).
Ex vivo splenocyte proliferation
At day 14 post immunization spleens from randomly chosen
quinpramine and vehicle treated EAN rats were dissected under
sterile conditions and passed through a 40 mm cell strainer
followed by ammonium chloride based erythrocyte lysis (BD
Bioscience). Derived responder splenocytes (2610
5/well) were
cultured in flat bottom 96-well plates in standard T cell medium
(IMDM, 5% fetal calf serum, 2 mM L-glutamine, 50 mM b-
mercaptoethanol, 100 U/ml Penicillin und 100 mg/ml Strepto-
mycin) in the presence of varying concentrations of BPNM (0.1–
100 mg/ml) in quadruplicate wells for 96 hours.
3H-Thymidin was
added for the last 24 hours and cell proliferation was measured by
detection of incorporated radioactivity as counts per minute.
Ovalbumin peptide-specific T cell proliferation
Mouse splenocytes were prepared from OTII mice expressing a
T cell receptor recognizing the MHC- II restricted Ovalbumin
peptide amino acids 323–339 (Ova323–339) (OTII cells) (Jackson
Laboratories, strain 004194). OTII cells were cryopreserved in
50% DMEM, 40% FCS and 10% DMSO and thawed
immediately before usage. Cocultures were prepared using
responder OTII cells and irradiated (1000 Gy) syngenic antigen
presenting cells (APC) (1.5610
5, respectively) in the presence of
Ova323–339 (10 mM, Peptides International) and proliferation was
measured by
3H-Thymidin incorporation. Either APCs or
responder cells were pre-incubated before coculturing with
quinpramine at varying dosages (0–200 nM) for 12 hours.
Combinations of differently pre-treated cells were tested for
proliferation in quadruplicate wells and two independent exper-
iments were performed.
Schwann cell culture
Conditionally immortalized mouse Schwann cell cultures were
maintained as previously described [20,21]. Schwann cells were
pre-treated with IFN-c (10 ng/ml, R&D Systems) for 24 hours
and incubated with quinpramine for further 1 to 24 hours at 1 to
500 nM. Schwann cells were stained for MHC class II (MHC-II,
Serotec MCA2687R) using a DyLight649 labelled goat-anti-
mouse secondary antibody (Serotec STAR74D649) and analyzed
by flow cytometry.
Flow Cytometry
For extracellular staining, splenocytes from quinpramine or
vehicle treated rats were co-stained for cell surface CD11b/c (BD
Quinpramine in EAN
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DyLight649 labelled goat-anti-mouse secondary antibody (Serotec
STAR74D649). For intracellular staining cells were first stained
with CD11b/c, fixed with 4% paraformaldehyde solution,
permeabilized with PermBuffer and subsequently stained for
intracellular MHC-II according to the manufacturers protocol
(BD Biosciences). To analyze the MHC-II distribution in vitro, rat
splenocytes of untreated and non-immunized rats were cultured in
the presence of 100 U/ml rat recombinant interferon (IFN)-c in
the presence or absence of quinpramine (100 nM). The percent-
age of MHC-II
+ cells and the fluorescence intensity of MHC-II
staining were assessed. Three independent experiments with
quadruplicate wells were performed. To assess the fluorescence
pattern of quinpramine and its precursor substances, splenocytes
were cultured under routine conditions for 1–6 hours in the
presence of quinpramine (100 nM), quinacrine (100 nM), imipra-
mine (100 nM) or a mixture of the later two (each at 100 nM).
Cells were washed three times with PBS and analyzed for
fluorescence in the channels FITC, PE, PerCP-Cy5.5, PE-Cy7,
APC, APC-Cy7, PacBlue, AmCyan. All flow cytometry was
performed using a FACSCanto II flow cytometer. Two indepen-
dent experiments with triplicate wells were performed. All flow
cytometry data were analyzed using FlowJo software (v7.2.5
TreeStar).
Figure 1. Quinpramine ameliorates clinical and histological features of EAN. (A) Severe EAN was induced in female Lewis rats by
subcutaneous immunization with bovine peripheral nerve myelin homogenisates (BPNM, 8 mg/animal). Animals were force fed by oral gavage with
quinpramine (2 mg/kg/week) three times per week from day 2 (Q preventive) or day 10 (Q therapeutic) after immunization or with vehicle alone
(n=10 per group). Clinical score ranging from 0 (healthy) to 10 (death) was assigned daily in a blinded fashion. Both preventive (grey squares) and
therapeutic (black dotted line) quinpramine treatment in comparison to vehicle alone (black points) significantly reduced maximum EAN severity and
disability. (B) Animals with moderate EAN (n=6 per group) received oral vehicle or quinpramine (2 mg/kg/week) treatment starting at day 10 after
immunization (Q therapeutic). Quinpramine treatment (blue triangles) significantly reduced peak severity of moderate EAN in comparison to vehicle
treatment (black points). Plots represent mean 6 SEM. (C) Sciatic nerves from randomly selected vehicle (left panel) and quinpramine (right panel)
treated EAN rats were dissected at day 14 after immunization and stained against CD68. Peripheral nerves from vehicle treated EAN rats (left panel)
exhibited multiple mononuclear cell infiltrates (red arrowheads). CD68
+ macrophages were found in infiltrates and diffusely distributed within the
endoneurium (red arrows). PNS from quinpramine treated EAN rats (right panel) did not contain relevant cellular infiltrates and only occasional CD68
+
cells (red arrow). Scale bars represent 25 mm. (D–F) The endoneurial area occupied by inflammatory infiltrates (D) and the endoneurial density of
CD68
+ (E) and MHC-II
+ cells (F) were significantly reduced in quinpramine treated animals. Plots represent mean 6 SEM. (G) Epoxy resin embedded
sciatic nerves of quinpramine treated EAN rats at day 14 after immunization were cut to semi thin (0.5 mm) sections. Nerves from vehicle treated EAN
rats exhibited mononuclear cell infiltration, myelin degradation and endoneurial oedema (left panel), while the PNS of quinpramine treated EAN rats
did not contain relevant infiltrates and myelin was well maintained (right panel). Scale bars represent 20 mm. * p,0.05, *** p,0.005.
doi:10.1371/journal.pone.0021223.g001
Quinpramine in EAN
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Data were statistically analyzed using GraphPadPrism 5.0
(GraphPad Software). The Wilcoxon-Mann-Whitney was used to
test for statistically significant differences in clinical score values.
Student’s t-test for unrelated samples was used to test for
statistically significant differences in all other analyses. Differences
were considered significant at p-values,0.05.
Results
Quinpramine ameliorates clinical and histological
manifestation of EAN
We first tested whether quinpramine – known to reduce
inflammation and clinical manifestation of EAE – would be
effective in inflammatory peripheral neuropathies. Severe EAN
w a si n d u c e di nf e m a l eL e w i sr a t sa n da n i m a l sr e c e i v e do r a l
quinpramine treatment by oral gavage by force feeding three
times per week. Quinpramine significantly reduced EAN peak
severity both when initiated early at day 2 after immunization
(preventive paradigm) (Fig. 1A) and when starting at day 10
after immunization at the onset of first clinical signs of EAN
(therapeutic paradigm) (Fig. 1A). In an independent experiment
we tested the potential of quinpramine to ameliorate EAN with
moderate peak severity equivalent to mild GBS. Here,
therapeutic quinpramine also significantly ameliorated EAN
(Fig. 1B). Moderate PNS inflammation may be easier to
influence therapeutically. We did not observe phenotypical
signs of toxicity in quinpramine treated animals. Preventive
treatment with the quinpramine precursor substance quinacrine
did not ameliorate clinical signs of EAN (Fig. S1), suggesting a
quinpramine specific effect. Subsequent ex vivo analyses were
restricted to samples from severe EAN experiments. In sciatic
nerve paraffin sections of vehicle treated, but not in quinpra-
mine treated animals we found widespread infiltration of
mononuclear cells (Fig. 1C). We found CD68 positive cells
distributed both diffusely and within mononuclear infiltrates at
lower frequencies in quinpramine treated animals (Fig. 1C). The
nerve cross sectional area occupied by mononuclear infiltrates
was significantly, approximately 5-fold reduced after quinpra-
mine treatment (Fig. 1D). The density of CD68 positive (Fig. 1E)
and of MHC-II positive (Fig. 1F) cells was significantly reduced
in quinpramine treated animals. In peripheral nerve semi-thin
sections we found preserved myelin integrity and also reduced
cellular infiltrates in quinpramine treated animals (Fig. 1G).
This indicates that quinpramine ameliorates EAN by reducing
peripheral nerve inflammation and reducing subsequent myelin
destruction.
Quinpramine reduces cell surface presence of MHC class
II on APCs in vivo
To approach the possible mechanism underlying quinpramine
therapy, we restimulated splenocytes from immunized rats with
myelin homogenisates. Splenocytes from rats treated with
quinpramine under a preventive paradigm had significantly lower
proliferatory responses (Fig. 2A). Proliferation also had a tendency
towards reduction in animals receiving therapeutic quinpramine,
that was significant at one of the four antigen concentrations tested
(1 mg/ml) (Fig. 2A). Given previous data that quinpramine
redistributes cholesterol raft associated proteins, we hypothesized
that quinpramine could reduce immune activation in EAN by
reducing cell surface availability of MHC class II molecules. To
experimentally test this hypothesis we compared the MHC-II
expression on ex vivo isolated splenocytes between the three
cohorts. Splenocytes from quinpramine treated animals had lower
percentages of MHC-II
+ cells in total and of CD11b/c
+ APCs
(Fig. 2B). On average, we found a significant reduction in the
percentage of total MHC-II
+ cells and in the proportion of MHC-
II
+ cells of CD11b/c
+ cells after preventive quinpramine treatment
(Fig. 2C). No difference was observed after therapeutic quinpra-
mine treatment. To differentiate between reduced MHC-II
expression and intracellular redistribution, we stained for extra-
cellular and total MHC-II expression. Cell surface expression of
MHC-II was significantly reduced in splenocytes from quinpra-
mine treated animals (Fig. 2D). Permeabilized cells stained for
total MHC-II exhibited an unchanged MHC-II expression
(Fig. 2E). The trend towards an even increased expression was
statistically not significant (Fig. 2E). This suggests that quinpra-
mine reduces cell surface availability of MHC-II - possibly by
intracellular redistribution - but not the overall MHC-II
expression.
Quinpramine reduces antigen specific proliferation
responses by reducing cell surface MHC class II
Extending previous reports, we studied the quinpramine effect
on intracellular cholesterol distribution. Quinpramine treated
macrophage cells had a tendency towards higher intracellular
cholesterol content than untreated cells as visualized by filipin
staining (Fig. 3A). In primary rat splenocytes quinpramine reduced
cell surface expression of MHC-II in all splenocytes and in
CD11b/c
+ APCs (Fig. 3B). In time course analyses, the reduction
of MHC-II expression was already significant after one hour and
increased with longer quinpramine exposure (Fig. 3C). In CD11b/
c
+ cells, the reduction of MHC-II expression was not time
dependent, but also statistically significant (Fig. 3D). Thus,
quinpramine reduced MHC-II cell surface expression on APCs
Figure 2. Quinpramine reduces antigen specific T cell proliferation and cell surface MHC class II availability in vivo. (A) Spleen cell
suspensions were generated from rats at peak EAN severity (d14 post immunization) treated with vehicle (n=4) or treated with quinpramine from
day 2 (Q preventive, n=4) or from day 10 after immunization (Q therapeutic, n=4). Splenocytes were restimulated with increasing concentrations of
bovine peripheral nerve myelin (BPNM) homogenate (0.1–100 mg/ml). Proliferation, as measured by
3H-thymidine incorporation, was significantly
reduced after preventive quinpramine treatment (blue triangles) in comparison to vehicle treatment (black dots). Splenocytes from therapeutically
treated animals (red squares) exhibited a partially significant trend at low antigen concentrations towards reduced proliferation. (B) Splenocytes from
vehicle and quinpramine treated rats at peak EAN severity were analyzed for extracellular MHC-II and CD11b/c expression and representative flow
cytometry contour plots are depicted. The percentage of total MHC-II
+ cells (top quadrants) and the percentage of MHC-II
+ cells of all CD11b/c
+ cells
(top right quadrant) were reduced after preventive quinpramine treatment in vivo. (C) The average proportion of MHC-II positive splenocytes (left
panel) and the average percentage of MHC-II positive cells of all CD11b/c
+ splenocytes (right panel) were significantly lower in animals having
received preventive quinpramine treatment (middle bars, mean 6 SEM) (n=6 per group). (D) Splenocytes were stained for cell surface MHC-II and
analyzed for mean fluorescence intensity. Splenocytes derived from quinpramine treated animals (Q, grey line) in comparison to controls (dotted
black line) had reduced cell surface MHC-II expression in representative flow cytometry histograms (left panel) and on average (right panel). (E)
Splenocytes from quinpramine treated animals (Q, grey line) exhibited an unchanged total extra- and intracellular MHC-II expression in comparison to
controls (dotted black line) in representative (left panel) and average (right panel) analyses. The total MHC-II staining trend towards increase was non-
significant. * p,0.05, *** p,0.005, ns not significant. All plots represent mean 6 SEM.
doi:10.1371/journal.pone.0021223.g002
Quinpramine in EAN
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murine macrophage cell line was cultured in the absence (left panel) or presence of quinpramine (200 nM, right panel) for six days before labelling
cholesterol with filipin. (B) Rat splenocytes were prestimulated with IFN-c and incubated with or without quinpramine and analyzed for extracellular
MHC-II and CD11b/c expression by flow cytometry (representative contour plots). In comparison to control cells (left panel), cells treated with
quinpramine (100 nM) for 3 hours (middle panel) and 24 hours (right panel) show reduced percentages of MHC-II
+ cells (top quadrants). (C) On
average the percentage of total MHC-II
+ cells was significantly reduced after 1 to 24 hours of quinpramine treatment (100 nM) in a time dependent
manner. (D) The proportion of MHC-II
+ cells of all CD11b/c
+ cells was significantly reduced after quinpramine treatment (100 nM). Reduction did not
change over time. * p,0.05, ** p,0.01 in comparison to controls. One representative out of four independent experiments is shown in A-D. (E)
Conditionally immortalized mouse Schwann cells incubated with quinpramine for 24 hours show dosage dependent reduction in average MHC-II
staining intensity. C control. (F) Irradiated splenocytes serving as antigen presenting cells (APCs) and responder splenocytes were generated from
Quinpramine in EAN
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professional APCs can be relevant in inflammatory neuropathies
[19,20]. Cell surface MHC-II expression on IFN-c prestimulated
cultured murine Schwann cells was reduced in a concentration
dependent manner (Fig. 3E). At the same time we observed that
cellular quinpramine uptake was well traceable by its green
fluorescence. We therefore used the fluorescence pattern of
quinpramine and its precursor substances to trace its uptake.
The pattern of fluorescence in quinpramine treated splenocytes
differed from the pattern returned from cells incubated with either
imipramine or quinacrine or a mixture of both (Fig. S2). This
indicates that quinpramine is taken up into the cells, but is not
cleaved into its precursor substances. To further assess the
functional relevance of MHC-II redistribution in APCs we
analyzed its target cell type using dissociated APC – T cell
cocultures from Ovalbumin specific T cell receptor transgenic
mice (Fig. 3G). Pre-treatment of APCs with quinpramine
significantly reduced antigen specific T cell proliferation, while
pre-treatment of only responder T cells did not affect proliferation
(Fig. 3F).
Discussion
We here demonstrate that quinpramine – a chimeric compound
derived from quinacrine and imipramine – reduces peripheral
nerve myelin specific autoimmune reactivity, peripheral nerve
inflammation, demyelination and clinical impairments in a rat
model of acute GBS. We further demonstrate that quinpramine
reduces the cell surface presence, but not expression, of MHC-II
molecules both in vitro and in vivo and therefore acts on APCs but
not on responder T cells. We hypothesize that a diminished
activation of myelin reactive T cells due to reduced MHC-II
present on APCs underlies the clinical effectiveness of the drug.
Especially since quinpramine is also clinically effective in our
therapeutic paradigm, this novel anti-inflammatory drug may offer
a future therapeutic option in inflammatory neuropathies. We
found the effect to be quinpramine specific and not mirrored by its
precursor substance quinacrine.
Quinpramine inhibits prion protein amplification [9] by altered
intracellular cholesterol distribution and changed composition of
cholesterol rich membrane domains – cholesterol rafts [9,22]. The
organization of antigen presenting and recognizing molecules at
the immunological synapse is an at least partially raft mediated
phenomenon [10,11] and requires a well orchestrated interplay of
antigen presenting and recognizing cells [23]. Therefore, a
compound redistributing cholesterol rich rafts to intracellular
compartments in a prion protein model could possibly also
influence immunological responses [12]. We here found indirect
evidence for such a mechanism: Quinpramine exerted its effect on
APCs, but not on responder T cells. By morphology, intracellular
cholesterol content appeared increased and by flow cytometry,
MHC-II molecules were shifted from cell surface to intracellular
compartments while total expression was unchanged. Although
other mechanisms cannot be excluded, our data suggest that such
an intracellular redistribution of MHC-II molecules may occur.
Our data well explain how preventive quinpramine ameliorates
EAN severity. Efficacy in the therapeutic treatment paradigm is
more surprising, however, given the incomplete reduction of
antigen specific proliferation (Fig. 2A) and unchanged percentage
of MHC-II
+ splenocytes (Fig. 2B, C). We speculate that two
applications of quinpramine are sufficient for a clinical benefit in
the therapeutic paradigm, but may not be sufficient to make the
alterations traceable in our analyses. The ex vivo analyses (Fig. 2)
mirror one time-point at day 14 post immunization (i.e. after two
days of treatment), while the clinical score reflects the cumulative
effect of more than 20 days of quinpramine treatment. This may
explain the discrepancy.
Quinpramine thus represents a candidate pharmaceutical to
possibly test in a clinical setting. In our therapeutic paradigm
already two applications of quinpramine (i.e. on day 10 and 12
after immunization) were sufficient to reduce peak EAN severity
on day 14 (Fig. 1A, B) suggesting a clinically fast and pronounced
effect. It is remarkable that quinpramine was thus effective even
after the priming phase in EAN is completed despite acting on
APCs. One may speculate that continued activation during the
effector stage of EAN remains relevant. Reduced MHC-II
expression on Schwann cells indicates that quinpramine may
reduce local T cell reactivation by conditional APCs. In our
moderate EAN experiment quinpramine reduced peak disease
severity more efficiently than in the severe EAN trial. Moderate
EAN may be easier to therapeutically modify. From a clinical
point of view quinpramine’s oral bioavailability and relatively
infrequent application are advantageous. We did not observe any
obvious toxicity, but the exact safety profile of quinpramine
remains unknown. Although we provide evidence that quinpra-
mine is not cleaved to its precursor substances after intracellular
uptake, one may speculate if quinpramine shares potential adverse
effects with its precursor substances (reviewed in [12]). Any
application of quinpramine to human subjects will require
extensive preceding safety testing.
Given that numerous compounds are effective in EAN, but
none of these has reached the bench-to-bedside transfer [8],
testing yet another compound may be critically questioned. Other
neuroinflammatory disorders, however, indicate that such a
transfer is possible [24,25] and the principal need for more
effective therapies is undoubted in GBS [3].
In conclusion, our data suggest that quinpramine represents a
possible candidate pharmaceutical to further establish in acute
inflammatory neuropathies and that quinpramine takes effect on
MHC class II expression on APCs. Such a mechanism may also be
effective in other autoimmune disorders and may extend our
therapeutic armentarium in autoimmune mediated disorders.
Supporting Information
Figure S1 Quinacrine treatment does not ameliorate EAN.
Moderate EAN was induced in female Lewis rats (n=6 per
group), who received oral vehicle or quinacrine (2 mg/kg/week)
treatment – one of the precursor substances of quinpramine –
starting at day 2 after immunization. Quinacrine treatment (green
inverted triangles) did not significantly alter severity or course of
moderate EAN in comparison to vehicle treatment (black points).
Plots represent mean 6 SEM.
(TIF)
Figure S2 Quinpramine treated cells exhibit a specific pattern of
fluorescence. (A) Cultured rat splenocytes were left untreated (red
Ova323–339 T cell receptor transgenic OTII mice (OTII cells) and separately incubated with increasing concentrations of quinpramine (from 0 to 200 nM)
for 24 hours. Combinations of cells pretreated with varying quinpramine concentrations (0–200 nM) were cocultured in the presence of 1 mg/ml
Ova323–339 for 72 hours and proliferation was measured by 3H-Thymidin incorporation for the last 24 hours. Average values from three independent
experiments are depicted. All non-indicated differences are statistically not significant. All plots represent mean 6 SEM.
doi:10.1371/journal.pone.0021223.g003
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21223line) or incubated for six hours with quinpramine (100 nM, green
line) or a mixture of quinacrine and imipramine (each 100 nM,
blue line) and analyzed by multicolor flow cytometry. Flow
cytometry histograms depict that both quinpramine and mixture
treated cells returned green fluorescence in the FITC (left panel)
and AmCyan (middle panel) channel. (B) Average fluorescence
intensities were calculated for each channel and quinpramine
(green bars), mixture of quinacrine and imipramine (blue bars) and
quinacrine only (yellow bars) all returned specific patterns of
fluorescence in the FITC (left panel) and AmCyan (middle panel)
channel. Imipramine (white bars) did not generate fluorescence in
comparison to untreated controls (red bars). Notably, a mixture of
quinacrine and imipramine did not return the same fluorescence
intensity as quinpramine alone indicating that quinpramine is not
cleaved to its precursors within the cells.
(TIF)
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